Cargando…

RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer

Ferroptosis is an iron-dependent, oxidative cell death, and is characterized by iron-dependent accumulation of reactive oxygen species (ROS) within the cell. It has been implicated in various human diseases, including cancer. Recently, ferroptosis, as a non-apoptotic form of cell death, is emerging...

Descripción completa

Detalles Bibliográficos
Autores principales: Sui, Xinbing, Zhang, Ruonan, Liu, Shuiping, Duan, Ting, Zhai, Lijuan, Zhang, Mingming, Han, Xuemeng, Xiang, Yu, Huang, Xingxing, Lin, Haoming, Xie, Tian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262051/
https://www.ncbi.nlm.nih.gov/pubmed/30524291
http://dx.doi.org/10.3389/fphar.2018.01371
_version_ 1783375034625032192
author Sui, Xinbing
Zhang, Ruonan
Liu, Shuiping
Duan, Ting
Zhai, Lijuan
Zhang, Mingming
Han, Xuemeng
Xiang, Yu
Huang, Xingxing
Lin, Haoming
Xie, Tian
author_facet Sui, Xinbing
Zhang, Ruonan
Liu, Shuiping
Duan, Ting
Zhai, Lijuan
Zhang, Mingming
Han, Xuemeng
Xiang, Yu
Huang, Xingxing
Lin, Haoming
Xie, Tian
author_sort Sui, Xinbing
collection PubMed
description Ferroptosis is an iron-dependent, oxidative cell death, and is characterized by iron-dependent accumulation of reactive oxygen species (ROS) within the cell. It has been implicated in various human diseases, including cancer. Recently, ferroptosis, as a non-apoptotic form of cell death, is emerging in specific cancer types; however, its relevance in colorectal cancer (CRC) is unexplored and remains unclear. Here, we showed that ferroptosis inducer RSL3 initiated cell death and ROS accumulation in HCT116, LoVo, and HT29 CRC cells over a 24 h time course. Furthermore, we found that ROS levels and transferrin expression were elevated in CRC cells treated with RSL3 accompanied by a decrease in the expression of glutathione peroxidase 4 (GPX4), indicating an iron-dependent cell death, ferroptosis. Overexpression GPX4 resulted in decreased cell death after RSL3 treatment. Therefore, RSL3 was able to induce ferroptosis on three different CRC cell lines in vitro in a dose- and time-dependent manner, which was due to increased ROS and an increase in the cellular labile iron pool. Moreover, this effect was able to be reversed by overexpression of GPX4. Taken together, our results suggest that the induction of ferroptosis contributed to RSL3-induced cell death in CRC cells and ferroptosis may be a pervasive and dynamic form of cell death for cancer treatment.
format Online
Article
Text
id pubmed-6262051
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-62620512018-12-06 RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer Sui, Xinbing Zhang, Ruonan Liu, Shuiping Duan, Ting Zhai, Lijuan Zhang, Mingming Han, Xuemeng Xiang, Yu Huang, Xingxing Lin, Haoming Xie, Tian Front Pharmacol Pharmacology Ferroptosis is an iron-dependent, oxidative cell death, and is characterized by iron-dependent accumulation of reactive oxygen species (ROS) within the cell. It has been implicated in various human diseases, including cancer. Recently, ferroptosis, as a non-apoptotic form of cell death, is emerging in specific cancer types; however, its relevance in colorectal cancer (CRC) is unexplored and remains unclear. Here, we showed that ferroptosis inducer RSL3 initiated cell death and ROS accumulation in HCT116, LoVo, and HT29 CRC cells over a 24 h time course. Furthermore, we found that ROS levels and transferrin expression were elevated in CRC cells treated with RSL3 accompanied by a decrease in the expression of glutathione peroxidase 4 (GPX4), indicating an iron-dependent cell death, ferroptosis. Overexpression GPX4 resulted in decreased cell death after RSL3 treatment. Therefore, RSL3 was able to induce ferroptosis on three different CRC cell lines in vitro in a dose- and time-dependent manner, which was due to increased ROS and an increase in the cellular labile iron pool. Moreover, this effect was able to be reversed by overexpression of GPX4. Taken together, our results suggest that the induction of ferroptosis contributed to RSL3-induced cell death in CRC cells and ferroptosis may be a pervasive and dynamic form of cell death for cancer treatment. Frontiers Media S.A. 2018-11-22 /pmc/articles/PMC6262051/ /pubmed/30524291 http://dx.doi.org/10.3389/fphar.2018.01371 Text en Copyright © 2018 Sui, Zhang, Liu, Duan, Zhai, Zhang, Han, Xiang, Huang, Lin and Xie. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Sui, Xinbing
Zhang, Ruonan
Liu, Shuiping
Duan, Ting
Zhai, Lijuan
Zhang, Mingming
Han, Xuemeng
Xiang, Yu
Huang, Xingxing
Lin, Haoming
Xie, Tian
RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer
title RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer
title_full RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer
title_fullStr RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer
title_full_unstemmed RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer
title_short RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer
title_sort rsl3 drives ferroptosis through gpx4 inactivation and ros production in colorectal cancer
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262051/
https://www.ncbi.nlm.nih.gov/pubmed/30524291
http://dx.doi.org/10.3389/fphar.2018.01371
work_keys_str_mv AT suixinbing rsl3drivesferroptosisthroughgpx4inactivationandrosproductionincolorectalcancer
AT zhangruonan rsl3drivesferroptosisthroughgpx4inactivationandrosproductionincolorectalcancer
AT liushuiping rsl3drivesferroptosisthroughgpx4inactivationandrosproductionincolorectalcancer
AT duanting rsl3drivesferroptosisthroughgpx4inactivationandrosproductionincolorectalcancer
AT zhailijuan rsl3drivesferroptosisthroughgpx4inactivationandrosproductionincolorectalcancer
AT zhangmingming rsl3drivesferroptosisthroughgpx4inactivationandrosproductionincolorectalcancer
AT hanxuemeng rsl3drivesferroptosisthroughgpx4inactivationandrosproductionincolorectalcancer
AT xiangyu rsl3drivesferroptosisthroughgpx4inactivationandrosproductionincolorectalcancer
AT huangxingxing rsl3drivesferroptosisthroughgpx4inactivationandrosproductionincolorectalcancer
AT linhaoming rsl3drivesferroptosisthroughgpx4inactivationandrosproductionincolorectalcancer
AT xietian rsl3drivesferroptosisthroughgpx4inactivationandrosproductionincolorectalcancer